Well its logical sense competition has to be kept in check. For instance Regeneron garnered a partnership deal with Avalanche biotech before the bad phase 2 data for macular degeneration. Regeneron partnered with it way before phase 2 had even started. But Regeneron did so because if Avalanche was successful with gene therapy it would have taken away from Elyea sales in the macular degeneration space.
It's common sense these big pharma companies defend the big positions they are in. In the case of Gilead it will defend itself vigorously not to lose its HIV profit. -- 44% of yearly revenue.
News 
Market Data 
Discover 
AI
